Biomea Fusion, Inc. (NASDAQ:BMEA) to Post Q1 2025 Earnings of ($0.82) Per Share, Capital One Financial Forecasts

Biomea Fusion, Inc. (NASDAQ:BMEA) – Equities research analysts at Capital One Financial issued their Q1 2025 EPS estimates for Biomea Fusion in a research note issued to investors on Friday, September 27th. Capital One Financial analyst N. Quibria forecasts that the company will post earnings per share of ($0.82) for the quarter. Capital One Financial has a “Overweight” rating and a $25.00 price objective on the stock. The consensus estimate for Biomea Fusion’s current full-year earnings is ($4.09) per share. Capital One Financial also issued estimates for Biomea Fusion’s Q2 2025 earnings at ($0.86) EPS and Q4 2025 earnings at ($0.84) EPS.

A number of other equities research analysts also recently weighed in on the stock. Piper Sandler dropped their price target on shares of Biomea Fusion from $45.00 to $10.00 and set an “overweight” rating for the company in a research report on Friday, June 7th. RODMAN&RENSHAW upgraded shares of Biomea Fusion to a “strong-buy” rating in a research report on Thursday, September 26th. Truist Financial upgraded shares of Biomea Fusion from a “hold” rating to a “buy” rating and set a $54.00 price target for the company in a research report on Friday. HC Wainwright boosted their price objective on shares of Biomea Fusion from $15.00 to $40.00 and gave the company a “buy” rating in a research report on Friday. Finally, Scotiabank boosted their price objective on shares of Biomea Fusion from $21.00 to $41.00 and gave the company a “sector outperform” rating in a research report on Friday. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Biomea Fusion currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.40.

Biomea Fusion Trading Up 2.0 %

NASDAQ BMEA opened at $10.10 on Monday. Biomea Fusion has a 1-year low of $3.61 and a 1-year high of $22.74. The company has a 50 day moving average of $6.99 and a 200-day moving average of $8.85. The company has a market cap of $363.04 million, a price-to-earnings ratio of -2.83 and a beta of -0.47.

Biomea Fusion (NASDAQ:BMEA) last released its quarterly earnings results on Wednesday, July 31st. The company reported ($1.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.03).

Institutional Trading of Biomea Fusion

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC bought a new stake in shares of Biomea Fusion during the second quarter worth $109,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Biomea Fusion during the second quarter worth $36,000. Scientech Research LLC bought a new stake in shares of Biomea Fusion during the second quarter worth $46,000. Squarepoint Ops LLC bought a new stake in shares of Biomea Fusion during the second quarter worth $237,000. Finally, DRW Securities LLC bought a new stake in shares of Biomea Fusion during the second quarter worth $55,000. Institutional investors own 96.72% of the company’s stock.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.